-transparent.png){kind=logo}
An immunoassay for thromboxane B2 was developed in which the hapten molecule was labeled with beta-galactosidase. The immunoprecipitate formed after competition between enzyme-labeled and unlabeled thromboxane B2 was subjected to a fluorometric assay of beta-galactosidase. Thromboxane B2 was detectable in the range of 0.1-30 pmol. Both enzyme immunoassay and radioimmunoassay showed essentially the same cross-reactivities with other prostaglandins and their metabolites when the same antibody was used. Known amounts of thromboxane B2 were added to human plasma, and the sample was applied to an octadecyl silica column. The extract was analyzed by enzyme immunoassay to examine the correlation between the added (x) and measured (y) thromboxane B2 (y = 1.09x + 11.07 pmol/ml, r = 0.99). A satisfactory correlation was observed between radioimmunoassay (x) and enzyme immunoassay (y) (y = 0.92x + 4.64 pmol/ml, r = 0.96). The validity of enzyme immunoassay was also confirmed by gas chromatography-mass spectrometry of a dimethylisopropylsilyl ether derivative of thromboxane B2 methyl ester. The method was applicable to the assay of thromboxane B2 produced from endogenous precursor during thrombin-induced aggregation of human platelets.
Y Hayashi, and
N Ueda, and
K Yokota, and
S Kawamura, and
F Ogushi, and
Y Yamamoto, and
S Yamamoto, and
K Nakamura, and
K Yamashita, and
H Miyazaki, and
K Kato, and
S Terao
January 1989,
Zeitschrift fur medizinische Laboratoriumsdiagnostik,
Y Hayashi, and
N Ueda, and
K Yokota, and
S Kawamura, and
F Ogushi, and
Y Yamamoto, and
S Yamamoto, and
K Nakamura, and
K Yamashita, and
H Miyazaki, and
K Kato, and
S Terao
January 1989,
Zeitschrift fur medizinische Laboratoriumsdiagnostik,
Y Hayashi, and
N Ueda, and
K Yokota, and
S Kawamura, and
F Ogushi, and
Y Yamamoto, and
S Yamamoto, and
K Nakamura, and
K Yamashita, and
H Miyazaki, and
K Kato, and
S Terao
October 1985,
Journal of biochemistry,
Y Hayashi, and
N Ueda, and
K Yokota, and
S Kawamura, and
F Ogushi, and
Y Yamamoto, and
S Yamamoto, and
K Nakamura, and
K Yamashita, and
H Miyazaki, and
K Kato, and
S Terao
June 1985,
Prostaglandins,
Y Hayashi, and
N Ueda, and
K Yokota, and
S Kawamura, and
F Ogushi, and
Y Yamamoto, and
S Yamamoto, and
K Nakamura, and
K Yamashita, and
H Miyazaki, and
K Kato, and
S Terao
January 1989,
Advances in prostaglandin, thromboxane, and leukotriene research,
Y Hayashi, and
N Ueda, and
K Yokota, and
S Kawamura, and
F Ogushi, and
Y Yamamoto, and
S Yamamoto, and
K Nakamura, and
K Yamashita, and
H Miyazaki, and
K Kato, and
S Terao
January 1983,
Advances in prostaglandin, thromboxane, and leukotriene research,
Y Hayashi, and
N Ueda, and
K Yokota, and
S Kawamura, and
F Ogushi, and
Y Yamamoto, and
S Yamamoto, and
K Nakamura, and
K Yamashita, and
H Miyazaki, and
K Kato, and
S Terao
July 1991,
Prostaglandins,
Y Hayashi, and
N Ueda, and
K Yokota, and
S Kawamura, and
F Ogushi, and
Y Yamamoto, and
S Yamamoto, and
K Nakamura, and
K Yamashita, and
H Miyazaki, and
K Kato, and
S Terao
January 1988,
Biomedica biochimica acta,
Y Hayashi, and
N Ueda, and
K Yokota, and
S Kawamura, and
F Ogushi, and
Y Yamamoto, and
S Yamamoto, and
K Nakamura, and
K Yamashita, and
H Miyazaki, and
K Kato, and
S Terao
December 1993,
Clinical chemistry,
Y Hayashi, and
N Ueda, and
K Yokota, and
S Kawamura, and
F Ogushi, and
Y Yamamoto, and
S Yamamoto, and
K Nakamura, and
K Yamashita, and
H Miyazaki, and
K Kato, and
S Terao
August 1991,
Thrombosis research,
